Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CAR ART

Financiado

Cerrado

Chimeric Antigen Receptor to generate Alloantigen specific Regulatory T cells an...

Chimeric Antigen Receptor to generate Alloantigen specific Regulatory T cells and promote allograft tolerance Organ transplantation is the best life-supporting treatment for terminal organ failure. Graft survival is however limited by rejection, a destructive process resulting from the response of recipient’s immune system against donor s... ver más

31/10/2019

CNRS

171K€

Presupuesto del proyecto: 171K€

Líder del proyecto

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 3 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-10-31

MSCA-IF-2016: Individual Fellowships

I+D

Cerrada hace 8 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

3 Participantes

CNRS

171.35K€ | Lider

UNIVERSITY OF BRITISH COLUMB...

UBC

78.81K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

THE ONE STUDY A Unified Approach to Evaluating Cellular Immunotherapy in S... 15M€ Cerrado

ECP TOLERANCE An Investigation into Tolerance Induction by Extracorporeal... 45K€ Cerrado

SAF2010-15062 MECANISMOS DE INDUCCION DE TOLERANCIA MEDIADOS POR CELULAS M... 145K€ Cerrado

Smart ProTcell Smart Immune ProTcell: first-in-class allogeneic thymus empo... 4M€ Cerrado

Allo-THYTECH Development and implementation in clinical practice of the a... 173K€ Cerrado

Rethyming Rebuilding the human thymus to create a tolerising system fo... 1M€ Cerrado

Duración del proyecto: 31 meses Fecha Inicio: 2017-03-22
Fecha Fin: 2019-10-31

Líder del proyecto

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 171K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Organ transplantation is the best life-supporting treatment for terminal organ failure. Graft survival is however limited by rejection, a destructive process resulting from the response of recipient’s immune system against donor specific alloantigens. Prevention of rejection currently relies on immunosuppressive drugs that lack antigen specificity and therefore increase the risk for infections and cancers. Induction of donor-specific tolerance would provide indefinite graft survival without morbidity and therefore represents the Grail of transplant immunologists. Tolerance has been obtained in experimental models with adoptive transfer of ex vivo-expanded CD4+FOXP3+ regulatory T cells (Treg). Preclinical studies have indicated that the potency and specificity of Treg therapy could be markedly enhanced by the use of Treg specific for donor alloantigens. Translation of this approach in the clinic has been hindered by the lack of clinically applicable strategies to generate sufficient numbers of potent donor-specific Tregs. To overcome this limitation, Pr Levings’ group (Child and Family Research Institute, Vancouver, Canada) has just recently successfully used chimeric antigen receptor (CAR) technology to redirect the specificity of human Treg toward a transplant-relevant antigen. The objective of the 2-year action is to assess the impact of alloantigen-specific CAR Treg on cellular and humoral alloimmune responses and their ability to promote allograft tolerance. The outgoing phase of the global fellowship will be performed in Pr Levings’ lab, and the return phase in Pr Glaichenhaus’ team (Institut de Pharmacologie Moléculaire et Cellulaire, Valbonne, France) where the researcher will get in few years a tenured position. The main ambition of the program is to provide key data for the development of a clinical trial with CAR Tregs in kidney transplantation.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores